CAIHF Stock Chart & Stats
$1.07
$0.00(0.00%)
At close: 4:00 PM EDT
$1.07
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.28 - $1.07
Previous CloseN/A
Volume79.00
Average Volume (3M)8.00
Market Cap
$265.81M
Enterprise Value$2.75K
Total Cash (Recent Filing)$37.25M
Total Debt (Recent Filing)$75.56M
Price to Earnings (P/E)10.8
Beta9.56
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding240,718,300
10 Day Avg. Volume0
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.85
Price to Sales (P/S)0.44
P/FCF Ratio8.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundThe substantial 2025 revenue rebound indicates renewed demand and operating traction across the animal-health and agribusiness value chain. If sustained, greater scale can improve fixed-cost absorption and strengthen the company’s distribution reach.
Improved ProfitabilityHigher operating and net margins show that the recent revenue recovery translated into better earnings conversion, not only sales growth. Sustained cost control and product mix improvement could support stronger internal funding and returns.
Conservative Balance SheetLower leverage and a growing equity base provide financial resilience for an investment holding company exposed to livestock and healthcare cycles. The stronger balance sheet reduces refinancing pressure and preserves capacity to support operations.
Bears Say
Gross Margin CompressionThe sustained gap between current and earlier gross margins suggests pricing pressure, higher input costs, or a less favorable product mix. This weakens the durability of earnings and could limit profit growth even when revenue expands.
Uneven Cash GenerationHistorically inconsistent cash generation indicates that reported earnings have not reliably converted into liquidity. Working-capital needs or reinvestment demands may therefore constrain financial flexibility if the current recovery loses momentum.
Volatile Earnings ProfileThe combination of a prior loss year and negative reported growth indicators shows that the 2025 rebound has not yet established a consistently compounding earnings base. Results remain exposed to livestock cycles, product demand, and execution.
Chia Tai Enterprises International News
CAIHF FAQ
What was Chia Tai Enterprises International Limited’s price range in the past 12 months?
Chia Tai Enterprises International Limited lowest stock price was $0.28 and its highest was $1.07 in the past 12 months.
What is Chia Tai Enterprises International Limited’s market cap?
Chia Tai Enterprises International Limited’s market cap is $265.81M.
When is Chia Tai Enterprises International Limited’s upcoming earnings report date?
Chia Tai Enterprises International Limited’s upcoming earnings report date is Nov 05, 2026 which is in 42 days.
How were Chia Tai Enterprises International Limited’s earnings last quarter?
Chia Tai Enterprises International Limited released its earnings results on Aug 11, 2026. The company reported $0.015 earnings per share for the quarter.
Is Chia Tai Enterprises International Limited overvalued?
According to Wall Street analysts Chia Tai Enterprises International Limited’s price is currently Overvalued.
Does Chia Tai Enterprises International Limited pay dividends?
Chia Tai Enterprises International Limited does not currently pay dividends.
What is Chia Tai Enterprises International Limited’s EPS estimate?
Chia Tai Enterprises International Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chia Tai Enterprises International Limited have?
Chia Tai Enterprises International Limited has 240,718,300 shares outstanding.
What happened to Chia Tai Enterprises International Limited’s price movement after its last earnings report?
Chia Tai Enterprises International Limited reported an EPS of $0.015 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chia Tai Enterprises International Limited?
Currently, no hedge funds are holding shares in CAIHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chia Tai Enterprises International Limited
Chia Tai Enterprises International Limited primarily produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operations are divided into two distinct divisions: Biochemical and Industrial. The Biochemical division focuses on the manufacturing and supply of CTC premix and CTC hydrochloride products. These are employed as feed supplements to encourage livestock growth, prevent or cure animal illnesses, and improve feed conversion, sold under the brands Shihao and Citifac. Conversely, the Industrial segment handles the sales, rental, and maintenance of heavy construction machinery, encompassing items such as excavators, power generators, bulldozers, compactors, and their spare parts. This division also fabricates and markets carburetors and other automotive components for various automobile and motorcycle manufacturers. Founded in 1987, the company maintains its headquarters in Central, Hong Kong, and functions as a subsidiary of Charoen Pokphand Foods Public Company Limited.
Technical Analysis
The United Laboratories International Holdings
―
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
Grand Pharmaceutical Group Limited
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors